Upstart maps plans to build fibrosis pipeline; FDA extends review period for Lilly’s baricitinib
• A group of academic investigators in Toronto, working through MaRS Innovation, are spinning out new tech to launch a biotech startup dubbed Fibrocor in partnership with Germany’s Evotec. Launched with about $2.1 million in seed money, they’ll work on identifying a lead program for fibrosis in 2018.
• The FDA will take some added time to review Eli Lilly’s application for baricitinib. The pharma giant has filed some added data analysis on the rheumatoid arthritis drug that regulators will need time to review.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.